<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048438</url>
  </required_header>
  <id_info>
    <org_study_id>2001-019</org_study_id>
    <nct_id>NCT00048438</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)</brief_title>
  <official_title>Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether paricalcitol is safe and effective&#xD;
      compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy endpoint is achievement of two consecutive &gt; or = 30% decreases from baseline iPTH levels.</measure>
  </primary_outcome>
  <enrollment>68</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paricalcitol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Under care of physician at least 2 months (for CKD)&#xD;
&#xD;
          -  Not on active Vitamin D therapy for at least 4 weeks prior&#xD;
&#xD;
          -  If female:&#xD;
&#xD;
               -  Not of childbearing potential, OR&#xD;
&#xD;
               -  Practicing birth control&#xD;
&#xD;
               -  Not breastfeeding&#xD;
&#xD;
          -  If taking phosphate binders, on a stable regimen at least 4 weeks prior&#xD;
&#xD;
          -  For entry into Pretreatment Phase:&#xD;
&#xD;
               -  iPTH at least 120 pg/mL&#xD;
&#xD;
               -  GFR of 15-60 mL/min and no dialysis expected for at least 6 months&#xD;
&#xD;
          -  For entry into Treatment Phase:&#xD;
&#xD;
               -  Average of 2 consecutive iPTH values of at least 150 pg/mL, taken at least 1 day&#xD;
                  apart (all values not less than 120 pg/mL&#xD;
&#xD;
               -  2 consecutive corrected serum calcium levels between 8.0-10.0 mg/dL&#xD;
&#xD;
               -  2 consecutive serum phosphorus levels of not more than 5.2 mg/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergic reaction or sensitivity to similar drugs&#xD;
&#xD;
          -  Acute Renal Failure within 12 weeks of study&#xD;
&#xD;
          -  Chronic gastrointestinal disease&#xD;
&#xD;
          -  Spot urine result demonstrating a urine-calcium-to-urine creatinine ratio of greater&#xD;
             than 0.2, or a history of renal stones&#xD;
&#xD;
          -  Taken aluminum-containing phosphate binders within last 12 weeks, or requires such&#xD;
             medication for more than 3 weeks during study&#xD;
&#xD;
          -  Current malignancy, or clinically significant liver disease&#xD;
&#xD;
          -  Active granulomatous disease (TB, sarcoidosis, etc.)&#xD;
&#xD;
          -  History of drug or alcohol abuse within 6 mos. prior&#xD;
&#xD;
          -  Evidence of poor compliance with diet or medication&#xD;
&#xD;
          -  Received any investigational drug or participated in any device trial within 30 days&#xD;
             prior&#xD;
&#xD;
          -  Taking maintenance calcitonin, bisphosphonates, or drugs that may affect calcium or&#xD;
             bone metabolism (other than females on stable estrogen and/or progestin therapy)&#xD;
&#xD;
          -  On glucocorticoids for a period of more than 14 days within the last 6 months&#xD;
&#xD;
          -  HIV positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Williams, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Nephrology</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outcomes Research International, Inc.</name>
      <address>
        <city>Hudson</city>
        <state>Florida</state>
        <zip>34667</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Association of South Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Nephrology Associates</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Health Sciences Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arms, Dodge, Robinson, Wilber and Crouch</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEA Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Nephrology Associates, PA</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney and Hypertension Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dorn VA Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Nephrology Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic, Inc., P.S.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University</name>
      <address>
        <city>Cracow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>October 31, 2002</study_first_submitted>
  <study_first_submitted_qc>November 1, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2002</study_first_posted>
  <last_update_submitted>August 10, 2006</last_update_submitted>
  <last_update_submitted_qc>August 10, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

